Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
2024 Acne Guidelines & Beyond: Isotretinoin
Description
The presentation provides an overview of the 2024 acne guidelines focused on isotretinoin, emphasizing the historical context of guidelines which aim to maintain the scope of practice for dermatologists. The speaker highlights the evolution of guidelines from the 1990s and discusses changes in the recommendations, including those regarding the use of isotretinoin for severe acne and its indication for patients who have not responded to standard treatments. The speaker critiques the shift to evidence-based guidelines, specifically the GRADE system, arguing that it introduces subjectivity and may bias against higher-cost treatments despite their effectiveness. Furthermore, the guidelines recommend monitoring for side effects such as inflammatory bowel disease, and studies have shown no increased risk associated with isotretinoin. Mood changes associated with isotretinoin usage are not significantly linked to depression or suicidal ideation; in fact, some studies suggest it may improve mood. The speaker also discusses updated monitoring protocols for triglycerides and liver function and changes to pregnancy testing regulations under the iPLEDGE program, emphasizing improvements in patient management. Ultimately, the guidelines support isotretinoin use for those deemed appropriate by practitioners without imposing restrictions that could hinder patient care.
View moreConclusions
- The 2024 guidelines for isotretinoin support its use for severe acne and patients with treatment-resistant or psychosocially burdensome conditions.
- There is no proven link between isotretinoin and inflammatory bowel disease (IBD).
- Mood changes are not negatively affected in the majority of patients taking isotretinoin, with studies suggesting potential mood improvements.
- Monitoring for side effects is necessary, but the guidelines advocate for individualized approaches based on patient response.
- Changes to the iPledge system have made it easier to manage pregnancy risk criteria for patients on isotretinoin.
- Tran PT et al, J Am Acad Dermatol, DOI: https://doi.org/10.1016/j.jaad.2020.10.030
- Kridin et al, J Am Acad Dermatol, https://doi.org/10.1016/j.jaad.2022.12.015
- Taylor et al, J Am Acad Dermatol, https://doi.org/10.1016/j.jaad.2023.01.014
- Kridin & Ludwig, J Am Acad Dermatol, https://doi.org/10.1016/j.jaad.2022.10.031
- Tan N, Tang A, Macalevey N, Tan B:JAMA Dermatol. doi: 10.1001/jamadermatol.2023.4579
- Baldwin, Marson* Int J Dermatol 2019; 59:279-83